Neurovance
Cambridge
About Neurovance
Neurovance is a clinical-stage neuroscience company that discovered and developed centanafadine (CTN) to help adults and children with ADHD. Neurovance has been funded in a venture capital investment by Novartis Venture Fund, Venture Investors, Tekla Capital Management, GBS Venture Partners, State of Wisconsin Investment Board (SWIB), and Timothy J. Barberich. It was founded in 2009 and is headquartered in Cambridge, Massachusetts.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $31.8M
- Funding stage: M&A
- Last round: Debt Financing (Jul 2016)
- Website: neurovance.com
- Phone: (617) 758-0300
Industries & Categories
Biotechnology, Clinical Trials, Health Care, Neuroscience
Canonical: https://fsome.com/organization/neurovance-188173 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.